Conference Coverage

EULAR COVID-19 recommendations set for update


 

FROM THE EULAR 2021 CONGRESS

The European Alliance of Associations for Rheumatology has started the process of updating their recommendations on how to manage patients with rheumatic and musculoskeletal diseases (RMDs) in the context of the SARS-CoV-2 pandemic.

Dr. Robert Landewé, a rheumatologist and professor of medicine at the University of Amsterdam

Dr. Robert Landewé

So far, the first part of the systematic literature review has been performed and the conclusions that have been drawn appear to back up the recommendations that have already been made. It’s “hard to say” if there will need to be changes, said Robert B.M. Landewé, MD, PhD, at the annual European Congress of Rheumatology, as the next phase will be for the task force members to meet and discuss the implications of the literature research.“I think there will only be minor modifications and a few novel recommendations, but that is personal opinion,” speculated Dr. Landewé, who is professor of rheumatology at the Amsterdam Medical Center, University of Amsterdam.

The recommendations, which were developed a little over a year ago and published in Annals of the Rheumatic Diseases, set out provisional guidance covering four themes: infection prevention, managing patients when social distancing measures are in effect, managing patients with RMDs who develop COVID-19, and the prevention of infections other than SARS-CoV-2.

Emphasis on quality of evidence

According to EULAR’s standard operating procedures “updates should only be done if the evolving evidence mandates to do so,” and be based on “rational arguments,” Dr. Landewé said. “The last year was a bit unprecedented in that regard as we didn’t have those rational arguments before we designed our first set of recommendations and, as you can expect, that is totally due to the character of the pandemic.”

So much has been published on COVID-19 since then it was time to reappraise the situation. The task force behind the recommendations met in January 2021 to discuss the results of the literature search that was centered around five main research questions.

  • Do patients with RMDs face more risk of contracting SARS-CoV-2 than the general population?
  • If patients contract the virus, do they have a worse prognosis?
  • Are antirheumatic medications associated with a worse outcome in people with RMDs?
  • Should patients continue their antirheumatic medications?
  • What evidence informs the use of vaccination against SARS-CoV-2 in patients with RMDs?

The latter research question is pending discussion since there were no studies to review at the time as the various vaccines had only just started to be widely available.

“We put a lot of emphasis on the quality of evidence,” Dr. Landewé said. In addition to making sure that patients did indeed have COVID-19 and checking that hospitalization and death records were caused by the disease, the task force team also looked to see if there was a control group being used. An extensive risk of bias assessment was undertaken, the results of which are pending.

Of 6,665 records identified during the literature search, just 113 full-text articles were assessed for eligibility. Of those, 60% were rejected as they did not pass the quality assessment, leaving 49 articles for consideration. The majority of these looked at the incidence of COVID-19, with others focusing on risk factors or both.

Pages

Recommended Reading

COVID-19: One Patient at a Time
Covid ICYMI
How COVID-19 affects peripartum women’s mental health
Covid ICYMI
Obstructive sleep apnea linked to COVID-19 risk
Covid ICYMI
GI symptoms and chronic fatigue may persist months after COVID-19
Covid ICYMI
Psychiatric fallout from long-COVID: How to prepare
Covid ICYMI
Hospitalists innovate in ICU management
Covid ICYMI
Children aged 12-15 years continue to close COVID-19 vaccination gap
Covid ICYMI
Visa worries intensify pandemic stress for immigrant hospitalist moms
Covid ICYMI
DOJ charges 14 with COVID-19–related fraud nearing $150M
Covid ICYMI
Subclinical myocarditis found in some athletes post COVID
Covid ICYMI